Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/1/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Richard A. Guarino

Wrong Dr. Richard A. Guarino?
 
Background

Employment History

  • President
    Oxford Pharmaceutical Services Inc
  • President
    Oxford Pharmaceutical Resources , Inc.
  • President and Chief Executive Officer
    Oxford Research International Corp.
  • Vice President and Medical Director
    Revlon Healthcare Group
  • Director of Clinical Research
    Sandoz Inc

Education

  • MD
  • M.D.
17 Total References
Web References
Dr. Richard A. Guarino, ...
www.hum-molgen.org, 14 Jan 2010 [cached]
Dr. Richard A. Guarino, President, Oxford Pharmaceutical Resources, Inc.
By Richard Guarino, Oxford ...
www.informahealthcarebooks.com, 1 June 2009 [cached]
By Richard Guarino, Oxford Pharmaceutical Resources, Totowa, New Jersey, USA
...
Richard Guarino is President of Oxford Pharmaceuticals, Inc., and was the former CEO of Oxford Research International Corp. He is the editor of Informa Healthcare's Fourth Edition of New Drug Approval Process, the first book to guide and recommend ways to expedite global new drug approval processes while also following meeting federal and industry requirements. Dr. Guarino is a member of the Lupus Erythematosus Foundation, the Cystic Fibrosis Foundation and the Columbus Foundation, Drug Information Association, Association of Clinical Research Professionals, and the Academy of Pharmaceutical Physicians and Investigators.
Richard A. Guarino, MD; ...
www.cfpa.com, 20 Jan 2007 [cached]
Richard A. Guarino, MD; President, Oxford Pharmaceutical Resources, Inc.
Dr. Richard A. Guarino is President of Oxford Pharmaceutical Resources, Inc., a Consulting Clinical and Regulatory Organization specializing in the planning, implementing and submitting INDs, NDAs, in the CTDs format. Dr, Guarino has 35 years of experience in new drug applications, marketing launches, pharmaceutical and product advertising, and FDA Liaison. He was formerly the President and CEO of Oxford Research International Corp. one of the largest CRO's in the United States. Besides serving as an adjunct professor at Fairleigh Dickinson University, he was a former Director of Clinical Research at Sandoz Pharmaceutical Inc, (Novartis) and held the position of Vice President/Medical Director at Revlon Healthcare Group. He has been acclaimed for his book, New Drug Approval Process, now in its 5th edition. It is the first book ever written to guide and recommend ways to expedite the new drug approval process while following all the requirements of the US Code of Federal Regulations, EU Directives and ICH Guidelines.
Dr. Guarino is a member of many professional societies and associations including the New Jersey and New York Academies of Medicine, The Royal Society of Medicine, the Columbus Citizens Foundation, the Presidential Advisory Cabinet at Fairleigh Dickinson University, the Lupus Erythematosus Foundation, the Cystic Fibrosis Foundation and the Sovereign Military Hospitaller Order of Saint John of Jerusalem of Rhodes and of Malta American Association, USA Drug Information Association (DIA), Association of Clinical Research Professionals (ACRP), and Academy of Pharmaceutical Physicians and Investigators (APPI).
Marplan Press Release
www.oxfordpharm.com, 1 Oct 1998 [cached]
Richard A. Guarino, M.D. Oxford Pharmaceutical Services Inc. (973) 256-0600
OXFORD PHARMACEUTICAL SERVICES ACQUIRES MARPLAN® (isocarboxazid) FROM HOFFMANN-LA ROCHE
Nutley, NJ and Clifton, NJ – October, 1998 – Hoffmann-La Roche Inc. and Oxford Pharmaceutical Services Inc., announced today that Oxford is acquiring ownership of the NDA for the antidepressant product Marplan ® (isocarboxazid) from Roche. Oxford will assume sales, marketing and distribution of Marplan ® November 13, 1998. Orders for Marplan ® should be directed to Oxford Pharmaceutical Services, Inc., 1 US Highway 46 West, Totowa, NJ 07512. Questions or requests for prescribing information on Marplan ® should be addressed to Dr. Richard Guarino - telephone number 973-256-0600, fax number 973-837-0572, e-mail guarino@oxfordpharm.com.
Marplan®, a monoamine oxidase (MAO) inhibitor, is indicated as a second-line treatment for depression. "Marplan ® is an important option for patients who are unresponsive to other antidepressants such as: SSRIs or traditional antidepressants like amitriptyline. Marplan ® has shown significant efficacy in treating depression, and, for certain patients, may offer relief from depression that they otherwise might not be able to achieve," said Richard A. Guarino, M.D., President of Oxford.
...
"We’re delighted to be able to offer this medication for sale once again," said Guarino.
Roche U.S. Pharmaceuticals : Virtual Newsroom : Current Press Releases : Oxford Pharmaceutical Services Acquires Marplan
www.rocheusa.com, 6 Jan 1999 [cached]
Marplan has shown significant efficacy in treating depression, and, for certain patients, may offer relief from depression that they otherwise might not be able to achieve," said Richard A. Guarino, M.D., President of Oxford.
...
"We're delighted to be able to offer this medication for sale once again," said Guarino.
...
Richard A. Guarino, M.D.Oxford Pharmaceutical Services Inc.(973) 777-2800
Other People with the name "Guarino":
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304